Pediatric Home Milrinone Use While Awaiting Heart Transplant
In the United States, about 40,000 children are born with congenital heart defects each year. Many of these children are receiving life-sustaining treatment in hospitals, but with medical advances, a unique population is benefiting from home inotrope use. Using PubMed and Embase, the literature on pediatric home milrinone use and nursing implications from 2011 through 2019 was reviewed and revealed a total of 14 sources, including peer-reviewed articles, national databases, and hospital guidelines. Findings concluded the use of milrinone at home in the pediatric heart failure population awaiting heart transplant is safe and effective. Careful coordination is necessary from numerous disciplines to establish a safe course of therapy. Providing future education to nurse practitioners and nurses on this unique population will result in clinicians providing safer and more effective care.
- Cardiotonic Agents, Caregivers - Education, Child, Continuing Education, Heart Failure - Drug Therapy - In Infancy and Childhood, Heart Transplantation - In Infancy and Childhood, Home Health Care, Milrinone - Therapuetic Use - In Infancy and Childhood, Nursing Role, Pediatric Care, Titrimetry, United States, Waiting Lists
DeCastro, J. (2020). Pediatric Home Milrinone Use While Awaiting Heart Transplant. Pediatric Nursing, 46 (3), 115-118. Retrieved from https://digitalrepository.chop.edu/advpractice/116